Literature DB >> 16982876

Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions.

Nadira Durakovic1, Karl B Bezak, Mario Skarica, Vedran Radojcic, Ephraim J Fuchs, George F Murphy, Leo Luznik.   

Abstract

Mouse models of minor histocompatibility Ag-mismatched bone marrow transplantation were used to study donor dendritic cell (DC) reconstitution after conditioning, variables influencing the persistence of residual host DCs in different compartments, their phenotype, and their role in governing donor lymphocyte infusion (DLI)-mediated alloresponses. Reconstitution of all splenic DC subsets occurred rapidly after bone marrow transplantation and before T cell reconstitution. However, in contrast to MHC-mismatched chimeras, residual host-derived DCs persisted in the cutaneous lymph nodes (CLNs) of MHC-matched chimeras despite the presence or addition of donor T cells to the graft. The phenotype of these residual host-derived DCs in CLNs was consistent with Langerhans' cells (LCs). We confirmed their skin origin and found near-complete preservation of host-derived LCs in the skin. Host-derived LCs retained their ability to continuously traffic to the CLNs, expressed homogeneously increased levels of costimulatory molecules, and could capture and carry epicutaneously applied Ags. To determine the role of residual host LCs in governing DLI-mediated alloresponses, we administered DLI alone or after topical application of the TLR7 ligand imiquimod, which is known to enhance the LC emigration from the skin. DLI administration resulted in a decrease in host-derived DCs in the CLNs and increased recruitment of donor-derived DCs to the skin, whereas imiquimod augmented their alloreactivity. These results suggest uniqueness of the MHC-matched setting in relation to the persistence of host-derived DCs in the skin and points to a previously unrecognized role of host-derived LCs in the induction of DLI-mediated graft-vs-host alloresponses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982876     DOI: 10.4049/jimmunol.177.7.4414

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

2.  Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.

Authors:  Nadira Durakovic; Vedran Radojcic; Mario Skarica; Karl B Bezak; Jonathan D Powell; Ephraim J Fuchs; Leo Luznik
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

Review 3.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Authors:  Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-24       Impact factor: 5.742

4.  Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.

Authors:  Edmund K Waller; Brent R Logan; Wayne A C Harris; Steven M Devine; David L Porter; Shin Mineishi; John M McCarty; Corina E Gonzalez; Thomas R Spitzer; Oleg I Krijanovski; Michael L Linenberger; Ann Woolfrey; Alan Howard; Juan Wu; Dennis L Confer; Claudio Anasetti
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

5.  Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation.

Authors:  Marco Mielcarek; Anna Yasmine Kirkorian; Robert C Hackman; Jeremy Price; Barry E Storer; Brent L Wood; Marylene Leboeuf; Milena Bogunovic; Rainer Storb; Yoshihiro Inamoto; Mary E Flowers; Paul J Martin; Matthew Collin; Miriam Merad
Journal:  Transplantation       Date:  2014-09-15       Impact factor: 4.939

6.  Whole-body UVB irradiation during allogeneic hematopoietic cell transplantation is safe and decreases acute graft-versus-host disease.

Authors:  Marina Kreutz; Sigrid Karrer; Petra Hoffmann; Eva Gottfried; Rolf-Markus Szeimies; Joachim Hahn; Matthias Edinger; Michael Landthaler; Reinhard Andreesen; Miriam Merad; Ernst Holler
Journal:  J Invest Dermatol       Date:  2011-08-18       Impact factor: 8.551

7.  The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.

Authors:  Ronjon Chakraverty; Megan Sykes
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

8.  Langerhans cells are not required for graft-versus-host disease.

Authors:  Hongmei Li; Daniel H Kaplan; Catherine Matte-Martone; Hung Sheng Tan; Srividhya Venkatesan; Kody Johnson; Anthony J Demetris; Jennifer McNiff; Mark J Shlomchik; Warren D Shlomchik
Journal:  Blood       Date:  2010-10-13       Impact factor: 22.113

9.  Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Lauren T Southerland; Ying Lu; Kataryna A Darlak; Cynthia R Giver; Douglas W McMillin; Wayne A C Harris; David L Jaye; Edmund K Waller
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

10.  The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.

Authors:  Marina G M Castor; Vanessa Pinho; Mauro M Teixeira
Journal:  Front Pharmacol       Date:  2012-02-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.